162 related articles for article (PubMed ID: 9721347)
21. Ascorbate plays a major role in labeling proteins with technetium-99m.
Thakur ML
J Nucl Med; 1994 Sep; 35(9):1566-8. PubMed ID: 8071714
[No Abstract] [Full Text] [Related]
22. Improved protein labeling by stannous tartrate reduction of pertechnetate.
Pettit WA; DeLand FH; Bennett SJ; Goldenberg DM
J Nucl Med; 1980 Jan; 21(1):59-62. PubMed ID: 7356741
[TBL] [Abstract][Full Text] [Related]
23. Current use and future potential of organometallic radiopharmaceuticals.
Schibli R; Schubiger PA
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1529-42. PubMed ID: 12397472
[TBL] [Abstract][Full Text] [Related]
24. The chemical state of 99m Tc in biomedical products. II. The chelation of reduced technetium with DTPA.
Eckelman WC; Meinken G; Richards P
J Nucl Med; 1972 Aug; 13(8):577-81. PubMed ID: 5041632
[No Abstract] [Full Text] [Related]
25. A new method of technetium-99m labeling of monoclonal antibodies through sugar residues. A study with TAG-72 specific CC-49 antibody.
Ranadive GN; Rosenzweig HS; Epperly MW; Seskey T; Bloomer WD
Nucl Med Biol; 1993 Aug; 20(6):719-26. PubMed ID: 8401372
[TBL] [Abstract][Full Text] [Related]
26. The influence of carrier on 99mTc radiopharmaceuticals.
Ballinger JR
Q J Nucl Med; 2002 Sep; 46(3):224-32. PubMed ID: 12134138
[TBL] [Abstract][Full Text] [Related]
27. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium.
Griffiths GL; Goldenberg DM; Jones AL; Hansen HJ
Bioconjug Chem; 1992; 3(2):91-9. PubMed ID: 1515475
[No Abstract] [Full Text] [Related]
28. Factors affecting chemistry of reduction-mediated 99mTc-labelling of monoclonal antibodies and polyclonal human immunoglobulins.
Boonkitticharoen V; Puchinda D; Ayudhya AN; Kraiphibul P
J Med Assoc Thai; 2001 Apr; 84(4):545-53. PubMed ID: 11460967
[TBL] [Abstract][Full Text] [Related]
29. Technetium-99m direct radiolabeling of monoclonal antibody ior egf/r3.
Morales AA; Crespo FZ; Gandolff GN; Iznaga Escobar N; Pérez NP; Hernández JC
Nucl Med Biol; 1998 Jan; 25(1):25-30. PubMed ID: 9466358
[TBL] [Abstract][Full Text] [Related]
30. Labelling of the anti-III-neurotubulin monoclonal antibody by 99mTc and its binding to responsible antigen.
Slapnicková K; Kolárová P; Kynclová K
Nucl Med Rev Cent East Eur; 2007; 10(1):1-5. PubMed ID: 17694493
[TBL] [Abstract][Full Text] [Related]
31. [Production of ready-to-use technetium (Tc)-99m and Tc99m-labeled radiopharmaceuticals].
Angelberger P
Strahlentherapie Sonderb; 1975; 74():457-60. PubMed ID: 53914
[No Abstract] [Full Text] [Related]
32. [Use of redox polymers for insulin labeling with technetium (99mTc)].
Komárek P; Kleisner I; Konopková M; Komárková I
Ceska Slov Farm; 1999 Sep; 48(5):218-20. PubMed ID: 10566241
[TBL] [Abstract][Full Text] [Related]
33. Direct 99mTc labeling of monoclonal antibodies: radiolabeling and in vitro stability.
Garron JY; Moinereau M; Pasqualini R; Saccavini JC
Int J Rad Appl Instrum B; 1991; 18(7):695-703. PubMed ID: 1787078
[TBL] [Abstract][Full Text] [Related]
34. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.
Bartholomä M; Valliant J; Maresca KP; Babich J; Zubieta J
Chem Commun (Camb); 2009 Feb; (5):493-512. PubMed ID: 19283279
[TBL] [Abstract][Full Text] [Related]
35. Site-specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m.
Stalteri MA; Mather SJ; Belinka BA; Coughlin DJ; Chengazi VU; Britton KE
Eur J Nucl Med; 1997 Jun; 24(6):651-4. PubMed ID: 9169572
[TBL] [Abstract][Full Text] [Related]
36. Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis.
Blankenberg FG; Vanderheyden JL; Strauss HW; Tait JF
Nat Protoc; 2006; 1(1):108-10. PubMed ID: 17406220
[TBL] [Abstract][Full Text] [Related]
37. Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies.
Pimm MV; Rajput RS; Frier M; Gribben SJ
Eur J Nucl Med; 1991; 18(12):973-6. PubMed ID: 1778209
[TBL] [Abstract][Full Text] [Related]
38. 99mTc-labeling of lipid vesicles containing the lipophilic chelator PE-DTTA: effect of tin-to-chelate ratio, chelate content and surface polymer on labeling efficiency and biodistribution behavior.
Tilcock C; Ahkong QF; Fisher D
Nucl Med Biol; 1994 Jan; 21(1):89-96. PubMed ID: 9234269
[TBL] [Abstract][Full Text] [Related]
39. The influence of chelator on the pharmacokinetics of 99mTc-labelled peptides.
Decristoforo C; Mather SJ
Q J Nucl Med; 2002 Sep; 46(3):195-205. PubMed ID: 12134136
[TBL] [Abstract][Full Text] [Related]
40. Determination of reduced disulfide groups in monoclonal antibodies.
Thakur ML; DeFulvio JD
Biotechniques; 1990 May; 8(5):512-6. PubMed ID: 2357374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
